Company to connect with its global network of partners at CPHI Milan, October 6th–8th.
SCHAUMBURG, Ill.– Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will attend CPHI Milan 2026, taking place October 6th–8th at Fiera Milano in Milan, Italy.
Over the past year, Avenacy has continued to expand its commercial portfolio, launching five new injectable products and further building out its Lidocaine Hydrochloride Injection, USP 1% portfolio. These additions reflect the Company’s continued focus on building a broad and resilient portfolio of critical injectable medications for the U.S. market.
“CPHI provides an important opportunity to spend time with the partners who have played an integral role in Avenacy’s growth,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “As we continue to build our business, maintaining strong relationships with our partners and identifying opportunities to create long-term value together remain important priorities. We look forward to connecting in Milan and discussing how we can continue to support the needs of the U.S. injectable market.”
At CPHI Milan, members of Avenacy’s leadership and business development teams will meet with current and prospective partners. These discussions will provide an opportunity to strengthen existing relationships, review ongoing programs and explore areas of potential future collaboration as Avenacy continues to advance its portfolio and long-term growth strategy.
Companies interested in meeting with Avenacy at CPHI Milan are encouraged to contact info@avenacy.com to schedule a meeting.
About Avenacy
Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality, FDA-approved injectable products to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.
Avenacy was launched in 2023 and is headquartered in Schaumburg, Illinois. For more information, please visit Avenacy.com.
Contacts
Media Contact
FTI Consulting
Avenacy@fticonsulting.com
